Does Medicare Advantage Cover Tresiba (Insulin Degludec)?

What Is Tresiba and Why Does It Matter for Medicare Patients?

Tresiba (insulin degludec) is a long-acting basal insulin approved by the FDA in September 2015 for adults and children aged 1 year and older with type 1 or type 2 diabetes. It carries a uniquely flat, peakless pharmacokinetic profile with a half-life exceeding 25 hours, allowing once-daily dosing at any time of day with a flexible injection window of up to 8 hours. That flexibility distinguishes it from insulin glargine U-100 (Lantus) and insulin detemir (Levemir), both of which require tighter adherence to injection timing.

The Medicare-enrolled population carries a heavy diabetes burden. The Centers for Disease Control and Prevention estimated in 2022 that 33% of Americans aged 65 and older have diagnosed diabetes, and a substantial share use basal insulin as a cornerstone of glycemic management (CDC National Diabetes Statistics Report 2022). For those patients, understanding exactly how their Advantage plan treats Tresiba can mean the difference between affordable daily dosing and a $510-per-month out-of-pocket bill.

The DEVOTE trial (N=7,637) compared insulin degludec U-100 head-to-head with insulin glargine U-100 in high-cardiovascular-risk patients with type 2 diabetes. At 2 years, degludec was non-inferior for major adverse cardiovascular events (MACE), while delivering a statistically significant 40% relative reduction in severe nocturnal hypoglycemia (rate ratio 0.60 to 95% CI 0.48-0.76, P<0.001) (Marso SP et al., NEJM 2017). Nocturnal hypoglycemia is particularly dangerous in older adults, where a single episode can precipitate falls, fractures, and emergency hospitalization. That clinical advantage is the most common medical justification physicians use when seeking prior authorization for Tresiba on a Medicare Advantage plan.

The FDA-approved prescribing information for Tresiba U-100 and U-200 is archived at the FDA accessdata label database, and reviewing the package insert before writing a PA letter is standard practice at HealthRX.

How Medicare Advantage (Part D) Formularies Treat Tresiba

Medicare Advantage plans deliver outpatient prescription drug coverage through an embedded Part D benefit, and each plan assembles its own formulary within CMS boundaries. Tresiba is not on the protected-class drug list, which means plans have full discretion to place restrictions on it or exclude it entirely.

In practice, most major carriers place insulin degludec on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with some smaller regional plans placing it on a specialty tier. Tier placement matters because it determines your cost-sharing at the pharmacy counter before the out-of-pocket maximum kicks in. A Tier 4 placement at a plan with a 33% coinsurance structure would generate roughly $168 per 30-day fill on a $510 list price, every month until the plan's annual deductible and out-of-pocket maximum are satisfied.

CMS's insulin cost-sharing rules, enacted through the Inflation Reduction Act, capped cost-sharing for covered insulin products at $35 per month beginning January 1, 2023, for Medicare Part D enrollees. If your plan's formulary lists Tresiba as a covered drug, even on a high tier, your monthly cost-sharing cannot exceed $35 per fill under that cap (CMS Insulin Affordability guidance). That single policy change significantly reduces the financial impact of high tier placement for beneficiaries who successfully get coverage.

Plans that do not list Tresiba at all represent a harder problem. A non-formulary drug can only be accessed through a formulary exception request, which requires a prescribing physician to document that every formulary alternative is medically contraindicated or clinically inappropriate for that specific patient.

Prior Authorization Criteria for Tresiba on Medicare Advantage

Prior authorization is required by nearly every Medicare Advantage plan that lists Tresiba. The specific criteria vary by carrier and plan year, but the following requirements appear consistently across major national carriers' publicly posted coverage policies.

Typical PA criteria include:

• A confirmed diagnosis of type 1 or type 2 diabetes mellitus with documentation in the medical record.
• An A1C value obtained within the prior 3-6 months, with a threshold commonly set at 7.5% or higher for initial approval.
• A prescribing clinician who is an MD, DO, or advanced practice provider with prescribing authority.
• Documentation that at least one formulary basal insulin (most commonly insulin glargine U-100 or biosimilar) was tried for a minimum of 90 days and either failed to achieve adequate glycemic control or caused clinically significant adverse effects.
• For patients with a documented history of severe nocturnal hypoglycemia, some plans waive the step therapy requirement if the physician provides supporting clinical notes and glucose logs.

The DEVOTE trial data become clinically relevant precisely here. Because degludec produced a 40% relative reduction in severe nocturnal hypoglycemia versus glargine U-100 in patients with high cardiovascular risk (Marso SP et al., NEJM 2017), a PA letter that references this trial and attaches a patient's hypoglycemia diary is substantially stronger than a generic request.

The HealthRX PA Support Framework for Tresiba organizes the documentation package into four components: (1) the clinical narrative tying the DEVOTE nocturnal hypoglycemia data to the individual patient's glucose log, (2) A1C and fasting glucose records from the prior 6 months, (3) a pharmacist-verified intolerance note if prior basal insulin caused injection-site reactions or severe hypoglycemia, and (4) a signed attestation from the prescribing physician confirming that formulary alternatives are clinically inappropriate. Plans that receive all four components at initial submission have a meaningfully shorter review cycle than those receiving incomplete packages.

Step Therapy Requirements and How to Address Them

Step therapy, sometimes called "fail first," requires patients to try one or more lower-cost alternatives before the plan authorizes the preferred drug. For Tresiba, virtually every plan with an active step therapy policy requires documented trial of at least one of the following basal insulins: insulin glargine U-100 (Lantus or a biosimilar such as Basaglar or Semglee), insulin detemir (Levemir), or NPH insulin.

The 90-day trial requirement is the most common threshold, though some plans use 60 days. "Failure" is typically defined as not reaching the patient's A1C goal or experiencing documented hypoglycemic events during the trial period. Both definitions offer a pathway for patients already established on Tresiba: a gap in therapy or a formulary switch mid-year does not erase prior clinical history.

CMS issued guidance under the 21st Century Cures Act instructing Medicare Advantage plans to grant step therapy exceptions when a prior authorization shows the required step would cause clinically significant harm. The American Diabetes Association's 2024 Standards of Care in Diabetes explicitly state that "insulin regimen selection should be individualized based on patient and disease factors," and that nocturnal hypoglycemia risk is a patient factor that clinicians must weigh (ADA Standards of Care 2024). That language is directly quotable in a step therapy exception letter.

Practically, a patient who switched from glargine U-100 to degludec because of recurring 3 a.m. hypoglycemia episodes already has the clinical evidence required. The physician's note documenting those events, paired with a glucose meter download, typically meets the evidentiary bar for a step therapy exception.

How to Appeal a Medicare Advantage Denial of Tresiba

A denial is not a permanent no. The Medicare Advantage appeals process has five levels, and most successful reversals happen at level one or level two.

Level 1: Plan Redetermination. Submit within 60 days of the denial notice. Include the physician's updated clinical letter referencing the specific denial reason cited in the Explanation of Coverage, DEVOTE trial data where applicable, and any new clinical documentation (glucose logs, A1C, hypoglycemia incident notes). The plan must respond within 7 calendar days for standard requests or 72 hours for expedited requests when a delay would seriously jeopardize health.

Level 2: Qualified Independent Contractor (QIC) Review. If the plan denies at Level 1, the QIC review is conducted by MAXIMUS Federal Services, the CMS-contracted independent reviewer for Medicare Part D appeals. Submit within 60 days of the Level 1 denial. MAXIMUS must issue its decision within 7 days (standard) or 72 hours (expedited). Published CMS data indicate that roughly 30-40% of Part D appeals that reach the QIC level are resolved in the beneficiary's favor when supported by physician documentation. MAXIMUS contact and submission instructions are available through CMS's official Medicare Appeals page.

Levels 3-5. Further escalation moves to an Administrative Law Judge hearing (Level 3, threshold $180 in 2024), the Medicare Appeals Council (Level 4), and federal district court (Level 5). Most patients do not need to reach these levels if Levels 1 and 2 are well-documented.

A critical practical point: ask your prescribing physician to submit an expedited request whenever the standard timeline would cause a dangerous gap in basal insulin therapy. Insulin is not a drug where a 7-day gap is clinically acceptable for most patients with type 1 diabetes or insulin-dependent type 2 diabetes.

Can You Use the Manufacturer Savings Card With Medicare Advantage?

No. Federal anti-kickback statutes prohibit drug manufacturers from offering copay assistance cards, coupons, or rebate programs to beneficiaries covered by federal health programs, including Medicare Advantage. Using a manufacturer savings card while enrolled in Medicare Advantage is a federal compliance violation, and pharmacies are trained to reject them.

The $35 monthly cap under the Inflation Reduction Act largely addresses the affordability concern for beneficiaries whose plans do list Tresiba as a covered drug. For patients whose plan does not cover Tresiba, the relevant options are:

1. The Novo Nordisk Patient Assistance Program (PAP), which is available at no cost to patients who meet income thresholds and do not have any coverage for the drug. Medicare beneficiaries with no Part D coverage for a specific drug may qualify. The program provides free medication directly from the manufacturer. Program details and income thresholds change annually and are verified at novonordisk-us.com.

2. Cash-pay pricing through pharmacy discount programs such as GoodRx, which lists insulin degludec at approximately $35 per month at select pharmacies depending on pack size and location. Cash-pay pricing is not tied to Medicare and carries no federal compliance risk.

3. Formulary exception and appeal, as described above, which remains the most direct pathway to sustained covered access.

Tresiba Dosing and Clinical Context for the Medicare Population

Understanding the clinical rationale behind Tresiba's prescribing patterns helps Medicare patients articulate their medical need during a PA or appeal.

Insulin degludec is available as Tresiba FlexTouch in two concentrations: U-100 (100 units/mL, 3 mL pen) and U-200 (200 units/mL, 3 mL pen). The U-200 pen delivers twice the insulin per pen unit compared to U-100, making it practical for patients requiring more than 60 units per day. Both concentrations are FDA-approved with the same dosing instructions: once daily at any time of day (FDA Tresiba Prescribing Information).

Starting doses for insulin-naive adults with type 2 diabetes are typically 10 units once daily, titrated upward every 3-4 days based on fasting glucose targets. For patients converting from another basal insulin, the conversion is generally unit-for-unit, though some patients converting from twice-daily insulin detemir may require dose adjustment. Clinical titration protocols vary by patient, and HealthRX physicians individualize these decisions during each telehealth visit.

For the Medicare population specifically, the flat pharmacokinetic profile of degludec reduces glycemic variability compared with glargine U-100. A crossover pharmacokinetic study published in Diabetes Care (N=66) demonstrated that insulin degludec produced a coefficient of variation in glucose infusion rate of 20% versus 82% for insulin glargine U-100 at steady state (Heise T et al., Diabetes Care 2012). Lower day-to-day variability translates to more predictable dosing adjustments and potentially fewer hypoglycemic episodes in older adults whose counterregulatory hormone responses may be blunted.

Tresiba for Weight Loss: What Medicare Will and Will Not Cover

Tresiba is not approved for weight loss and Medicare will not authorize it for that indication under any circumstance. This is a hard line in CMS policy. Part D plans are explicitly prohibited from covering drugs approved solely for weight loss or anorexia (CMS Part D Benefit Manual, Chapter 6), and insulin degludec's approved indications are limited to glycemic control in type 1 and type 2 diabetes.

Some patients ask whether the GLP-1 receptor agonist class, specifically semaglutide 2.4 mg (Wegovy), falls under a similar coverage exclusion. Wegovy received a cardiovascular outcomes indication in March 2024 following the SELECT trial (N=17,604), which showed a 20% relative risk reduction in MACE in overweight or obese adults without diabetes (Lincoff AM et al., NEJM 2023). CMS subsequently indicated that Part D plans may cover Wegovy for the cardiovascular indication. That policy does not extend to Tresiba or any other basal insulin.

Patients who are both insulin-dependent and interested in GLP-1 therapy for cardiometabolic benefit should discuss semaglutide 0.5-2.0 mg (Ozempic), which carries a separate glycemic indication and is covered under Part D for type 2 diabetes on most formularies.

Choosing the Right Medicare Advantage Plan If Tresiba Is Your Preferred Insulin

Plan selection during open enrollment (October 15 to December 7 each year) or a Special Enrollment Period is the most proactive step a Tresiba-dependent patient can take. CMS's Medicare Plan Finder tool at medicare.gov allows beneficiaries to enter their specific medications and receive a side-by-side comparison of cost-sharing, formulary tier, and restriction requirements across all available plans in their ZIP code.

When comparing plans, look specifically for the following in each plan's formulary:

• Whether insulin degludec appears at all (non-listed drugs require a formulary exception, a harder bar than a standard PA).
• The tier assignment, because even with the $35 cap, a non-covered drug generates 100% out-of-pocket cost.
• Whether a PA or step therapy restriction is noted in the formulary column.
• The plan's annual deductible for non-preferred brands, which can affect the timing of when the $35 cap takes effect.

Switching plans mid-year is only possible with a qualifying Special Enrollment Period trigger, so the annual enrollment decision carries full-year consequences. A Medicare counselor through the State Health Insurance Assistance Program (SHIP), available in all 50 states, can assist with plan comparison at no charge.